Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 98kWORD 18k
16 March 2018
E-007748/2017(ASW)
Answer given by Mr Oettinger on behalf of the Commission
Question reference: E-007748/2017

The Commission, with input from the European Medicines Agency (EMA), is currently fine-tuning its first initial assessment of the total costs of EMA's move from London to Amsterdam, notably by making a distinction between removal and relocation costs(1). This initial assessment will also show whether the Commission will need to submit a proposal to the budgetary authority to pre-finance some of the agency's relocation costs from the EU budget.

Concerning costs for the Agency's new permanent premises in Amsterdam, the Agency, with the Commission’s assistance, will present its building file on EMA to the Budgetary Authority in accordance with Article 88 of the Financial Regulation.

(1)Assessments of costs are without prejudice to ongoing negotiations between the EU and the UK on a withdrawal agreement, including on financing compensations.

Last updated: 7 June 2018Legal notice